Q3 EPS Estimate for Tonix Pharmaceuticals Boosted by Analyst

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) – Investment analysts at Zacks Research increased their Q3 2026 earnings per share (EPS) estimates for Tonix Pharmaceuticals in a research note issued on Wednesday, September 2nd. Zacks Research analyst D. Bautz now anticipates that the company will post earnings of ($2.50) per share for the quarter, up from their prior forecast of ($2.63). The consensus estimate for Tonix Pharmaceuticals’ current full-year earnings is ($10.03) per share. Zacks Research also issued estimates for Tonix Pharmaceuticals’ Q4 2026 earnings at ($2.28) EPS, FY2026 earnings at ($10.03) EPS, FY2027 earnings at ($5.48) EPS and FY2028 earnings at $1.86 EPS.

Several other brokerages have also weighed in on TNXP. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $27.00 price target on shares of Tonix Pharmaceuticals in a research report on Monday, August 10th. Finally, Weiss Ratings cut Tonix Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 28th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $24.50.

Tonix Pharmaceuticals Trading Down 2.5%

Tonix Pharmaceuticals stock opened at $12.83 on Thursday. Tonix Pharmaceuticals has a 1 year low of $9.40 and a 1 year high of $31.55. The company has a market cap of $220.03 million, a PE ratio of -0.99 and a beta of 1.74. The company’s 50-day moving average is $12.13 and its two-hundred day moving average is $12.87.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Monday, August 10th. The company reported ($2.44) EPS for the quarter, topping analysts’ consensus estimates of ($2.64) by $0.20. The firm had revenue of $13.54 million during the quarter, compared to analyst estimates of $7.72 million. Tonix Pharmaceuticals had a negative return on equity of 68.99% and a negative net margin of 548.64%.

Hedge Funds Weigh In On Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System increased its position in shares of Tonix Pharmaceuticals by 221.9% in the second quarter. California State Teachers Retirement System now owns 2,437 shares of the company’s stock worth $31,000 after purchasing an additional 1,680 shares during the period. Bank of New York Mellon Corp acquired a new stake in Tonix Pharmaceuticals during the second quarter worth about $533,000. State of Wyoming acquired a new stake in Tonix Pharmaceuticals during the fourth quarter worth about $27,000. Russell Investments Group Ltd. bought a new position in Tonix Pharmaceuticals in the 3rd quarter valued at about $29,000. Finally, BNP Paribas Financial Markets bought a new position in Tonix Pharmaceuticals in the 2nd quarter valued at about $65,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Seth Lederman purchased 2,000 shares of Tonix Pharmaceuticals stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $13.79 per share, for a total transaction of $27,580.00. Following the purchase, the chief executive officer directly owned 11,005 shares of the company’s stock, valued at $151,758.95. This trade represents a 22.21% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders have bought 4,415 shares of company stock valued at $55,108. 2.00% of the stock is currently owned by corporate insiders.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.